RCS - Oxford BioDynamics - OBD’s Oxford Lab accredited by UKAS

Oxford BiodynamicsAnnouncement

09/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250509:nRSI9773Ha&default-theme=true

RNS Number : 9773H  Oxford BioDynamics PLC  09 May 2025

 

 

 

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

OBD's Oxford Lab accredited by UKAS to run EpiSwitch® Clinical Tests in the
UK

·     OBD's facility in Oxford has been accredited by UKAS as clinical
lab under the ISO 15189 standard

·     Clinical validation of EpiSwitch CiRT has been completed in the
Oxford lab, further improving the test result turnaround time

·     All orders for both CiRT and PSE in the UK and Europe will be
processed within the UK lab

Oxford, UK - 9 May 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics platform, announces
that its UK facility in Oxford has been accredited by the United Kingdom
Accreditation Service (UKAS) as a clinical laboratory under the ISO 15189
standard.

The Company is also pleased to confirm the successful completed validation of
its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) as a clinical test in
this UK laboratory. CiRT is OBD's best-in-class stratification tool that
empowers clinicians to identify which patients are likely to respond to a
widely used class of immunotherapies:  immune checkpoint inhibitors. The CiRT
blood test is already available in the UK, but up to now, testing was
performed in OBD's US CLIA-certified facility.

Thomas Guiel, Chief Operating Officer of OBD, said:

"The immediate benefit for cancer patients seeking a CiRT test in
the UK will be the significant reduction in the elapsed time from receipt of
an order to result, which will now be 3-5 days. UKAS accreditation of our
clinical lab in the UK under ISO15189 is a significant milestone that
underscores our dedication to delivering high-quality and timely diagnostic
testing to support healthcare providers and patients in the UK and Europe,
meeting the stringent ISO requirements for patient testing and data security."

The successful validation of CiRT in the UK is an important advance for OBD's
British partners and customers, including its strategic partner, Bupa UK(1).

This milestone completes OBD's strategy to implement clinical testing
operations at its UK base, commissioned in April 2024.

More information on CiRT may be found at www.myCiRT.com
(https://www.mycirt.com/) .

- Ends -

References

1: Oxford BioDynamics Plc. (Oct 2023). Bupa UK to cover EpiSwitch® CiRT for
customers.
https://otp.tools.investis.com/clients/uk/oxford_biodynamics_plc/rns/regulatory-story.aspx?cid=2040&newsid=1726458
(https://otp.tools.investis.com/clients/uk/oxford_biodynamics_plc/rns/regulatory-story.aspx?cid=2040&newsid=1726458)

 

 

For more information:

 Oxford BioDynamics PLC                                              +44 (0)1865 518910

 Iain Ross Executive Chairman

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser and Broker                        +44 (0)20 7408 4090

 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy

 WG Partners - Joint Broker                                          +44 (0)20 3705 9330

 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

 OAK Securities - Joint Broker                                       +44 (0)20 3973 3678

 Jerry Keen / Henry Clarke / Damion Carruel

 Camarco - Financial PR                                              +44 (0)20 3757 4980

 Marc Cohen / Tilly Butcher / Fergus Young                           OBDFinancial@camarco.co.uk

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSIESAEISEEI